Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2020. View 4,000+ financial data types. Selling, general and administrative expense: Change in fair value of contingent consideration (3), (Gains) and losses related to strategic equity investments (5), Non-GAAP earnings per common share - diluted, Shares used in computing diluted earnings per common share (GAAP), Shares used in computing diluted earnings per common share (non-GAAP). A high-level overview of Alexion Pharmaceuticals, Inc. (ALXN) stock. This pandemic has had, and will undoubtedly continue to have near-term and lasting impacts on our business and ways of operating, but I am proud of the way our teams have responded during this challenging time. Interactive chart of Alexion Pharmaceuticals (ALXN) annual worldwide employee count from 2006 to 2020. Alexion Pharmaceuticals annual/quarterly net income history and growth rate from 2006 to 2020. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Full guidance updates are outlined below. See insights on Alexion Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Investment Thesis. Alexion shareholders will own around 15% of AstraZeneca's outstanding shares when the deal closes in the third quarter of next year. Do the numbers hold clues to what lies ahead for the stock? Basic data (GAAP): Revenue was $1.59 billion, up 10% sequentially from $1.44 billion and up 26% from $1.26 billion in the year-earlier quarter. Alexion's non-GAAP income tax expense for the three months ended March 31, 2020 and 2019 excludes the tax effect of pre-tax adjustments to GAAP profit. Non-GAAP R&D expense was $204.6 million, compared to $148.7 million in the second quarter of 2019. Megan Goulart, 857-338-8634 It employs around 2,400 people worldwide. Executive Director, Corporate Communications, Investors We also made significant progress diversifying our portfolio through business development, with the close of the Achillion acquisition and the announcement that we have entered into an agreement to acquire Portola," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. BOSTON--(BUSINESS WIRE)--Oct. 29, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2020. Alexion is continually monitoring the evolving situation and adjusting our operations as needed to support the safety and well-being of our employees and the patients and communities we serve. We remain focused on continuing to serve patients, protecting the health and safety of our employees and the communities in which we live and work, and supporting patients in clinical trials. BOSTON--(BUSINESS WIRE)--May 6, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2020. 2. Thanks to their dedication, I am confident we will be able to continue executing on our strategy and delivering long-term shareholder value by advancing our mission of developing and delivering transformative medicines.". Alexion Pharmaceuticals ALXN. Alexion Pharmaceuticals's operated at median revenue of $3.551 billion from fiscal years ending December 2015 to 2019. Alexion Pharmaceuticals annual and quarterly EBITDA history from 2006 to 2020. STRENSIQ net product sales were $184.3 million, compared to $141.3 million in the second quarter of 2019, representing a 30 percent increase. Head of Investor Relations, We use cookies to give you the best online experience. We continue to take steps to proactively respond to the evolving COVID-19 pandemic and to plan for related uncertainties. ULTOMIRIS net product sales were $251.1 million, compared to $54.2 million in the second quarter of 2019, representing a 363 percent increase. BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2020. Do the numbers hold clues to what lies ahead for the stock? Total revenues in the first quarter were $1,444.8 million, a 27 percent increase compared to the same period in 2019. It has been about a month since the last earnings report for Alexion Pharmaceuticals (ALXN Quick Quote ALXN - Free Report) .Shares have lost … This … GAAP impairment of intangible assets was $2,053.3 million primarily related to an impairment charge recorded during the second quarter 2020 related to the KANUMA intangible asset. Updated 2020 financial guidance excludes the impact of the recently announced agreement to acquire Portola. BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2020. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. "We had a strong first quarter across our global commercial business, driven by substantial growth in the number of patients we're treating with our medicines. During the three months ended March 31, 2020 and March 31, 2019, we recognized unrealized losses (gains) of 9.2 million and $(33.8) million, respectively, in investment income to adjust our strategic equity investments to fair value. Alexion Pharmaceuticals plans to raise its 2020 full-year revenue guidance by more than $200 million and is targeting global revenues of between $9 and $10 billion by 2025. In depth view into Alexion Pharmaceuticals Revenue (TTM) including historical data from 1996, charts, stats and industry comps. ET. Current and historical gross margin, operating margin and net profit margin for Alexion Pharmaceuticals (ALXN) over the last 10 years. We are also focused on minimizing potential interactions that could contribute to the spread of the virus and put additional strain on healthcare systems through the use of innovative virtual means where possible. The second quarter of 2020 includes impairment charges of $2,053.3 million primarily relating to the KANUMA intangible asset as a result of the Company's revised strategic view of KANUMA. Contents: Prepared Remarks; Questions and Answers; … Please refer to the attached Reconciliations of GAAP to non-GAAP Financial Results and GAAP to non-GAAP 2020 Financial Guidance for explanations of the amounts adjusted to arrive at non-GAAP net income and non-GAAP earnings per share amounts for the three and six month periods ended June 30, 2020 and 2019 and projected twelve months ending December 31, 2020. Innovation Index rank: 7 Invention Index rank: 24. Total revenues in the first quarter were $1,444.8 million, a 27 percent increase compared to the same period in 2019. Net product sales were $1,444.5 million in the second quarter of 2020, compared to $1,202.5 million in the second quarter of 2019. Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Alexion Pharmaceuticals revenue for the twelve months ending December 31, 2020 was … Non-GAAP SG&A expense was $253.6 million, compared to $255.8 million in the second quarter of 2019. The COVID-19 pandemic continues to significantly impact the global communities in which we live and work, and healthcare systems in particular. The consensus earnings per share (EPS) of $2.59/share is based on a poll of 19 analysts and represents a decline in… TABLE 1: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS, Cost of sales (exclusive of amortization of purchased intangible assets), Amortization of purchased intangible assets, Change in fair value of contingent consideration, Shares used in computing earnings per common share, TABLE 2: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS, Upfront payments related to licenses and other strategic agreements (1). WASHINGTON (dpa-AFX) - Alexion Pharmaceuticals Inc. (ALXN) announced earnings for first quarter that fell from the same period last year.The company's bottom line totaled $557.6 million, or $2.50 GAAP income tax benefit for the second quarter 2020 includes a deferred tax benefit of $377.3 million associated with the impairment charge related to the KANUMA intangible asset. GAAP cost of sales was $144.9 million, compared to $99.2 million in the second quarter of 2019. Alexion Pharmaceuticals Inc. ALXN announced that the FDA has approved a new advanced formulation of Ultomiris (ravulizumab-cwvz). … Alexion, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.44 billion for the quarter ended June 2020, … Alexion Pharmaceuticals (ALXN) came out with quarterly earnings of $3.22 per share, beating the Zacks Consensus Estimate of $2.70 per share. Alexion Pharmaceuticals has 3,082 employees across 23 locations and $6.07 B in annual revenue in FY 2020. We are also focused on minimizing potential interactions that could contribute to the spread of the virus and put additional strain on healthcare systems through the use of innovative virtual means wherever possible. Dezember 2020 hat AstraZeneca PLC (AstraZeneca) bestätigt Alexion Pharmaceuticals Inc. (Alexion) im Rahmen eines Cash-and-Share Deals im Wert von $40,2 bn zu akquirieren. © 2021 Alexion Pharmaceuticals, Inc. https://www.businesswire.com/news/home/20200506005293/en/, Received positive CHMP opinion for ULTOMIRIS, Advanced ULTOMIRIS as standard of care in PNH with more than 67% patient conversion from SOLIRIS, Further diversified development-stage and commercial-stage portfolios with close of Achillion acquisition and announced agreement to acquire Portola, Provided update on COVID-19 related activities and impact. Alexion is decreasing total revenues and EPS guidance and increasing non-GAAP operating margin guidance. "As a result of execution and delivery against our objectives, we have entered a new phase of company growth and diversification, which enables us to adjust our capital allocation priorities and return value to shareholders through an expanded stock buyback program. In addition to financial information prepared in accordance with GAAP, this press release also contains non-GAAP financial measures that Alexion believes, when considered together with the GAAP information, provide investors and management with supplemental information relating to performance, trends and prospects that promote a more complete understanding of our operating results and financial position during different periods. The New Haven-born company, which announced the plans ahead of its Virtual Investor Day on Tuesday, also said it expects to return at least $3 billion to shareholders through a multi-year stock buyback program. Alexion Pharmaceuticals's revenue increased in each of the last five fiscal years from 2.604 billion in 2015 to 4.991 billion in 2019. "As COVID-19 continues to reach across the globe, we are adapting our ways of working to ensure we maintain our ability to continue serving patients. Earlier in the day, O’Neill had announced a €450 million investment by Alexion Pharmaceuticals to build a … Alexion will host a conference call/audio webcast to discuss the first quarter 2020 results today at 8:00 a.m. Eastern Time. Total revenues in the second quarter were $1,444.6 million, a 20 percent increase compared to the same period in 2019. Alexion expects a 2025 revenue target of $9 billion to $10 billion, a 16% compound annual revenue growth rate by the end of 2020 and a CAGR of at least a 10% for revenue … These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for, or superior to, the financial measures prepared and presented in accordance with GAAP, and should be reviewed in conjunction with the relevant GAAP financial measures. Full guidance updates are outlined below. TABLE 3: RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL GUIDANCE, (in millions, except per share amounts and percentages), Gains and losses related to strategic equity investments, Diluted non-GAAP earnings per common share, Costs and expenses and margin (% total revenues), Non-GAAP research and development expense, GAAP selling, general and administrative expense, Non-GAAP selling, general and administrative expense, Income tax expense (% of income before income taxes), Tax effect of pre-tax adjustments to GAAP net income, TABLE 5: CONDENSED CONSOLIDATED BALANCE SHEETS, Prepaid expenses and other current assets, Total liabilities and stockholders' equity, TABLE 6: CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS. Updated 2020 financial guidance assumes a GAAP effective tax rate of (27.0) to (26.0) percent and a non-GAAP effective tax rate of 15.5 to 16.5 percent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion Pharmaceuticals was part of our Out Of Favor Health Care Stocks theme, which includes healthcare and pharma companies that have shown strong historical revenue … Alexion Pharmaceuticals ALXN. This press release contains forward-looking statements, including statements related to: guidance regarding anticipated financial results for 2020 (and the assumptions related to such guidance); our expectations regarding the affects COVID-19 will have on our business and operations, including clinical trials and product supply; the strength of our business and continued growth; the Company's capital allocation strategy; plans to expand the Company's pipeline; future plans for, and the timing for, the commencement of future clinical trials and the expected timing of the receipt of results of certain clinical trials and studies, including clinical programs for ULTOMIRIS, a higher concentration formulation of ULTOMIRIS, a subcutaneous administration of ULTOMIRIS, SOLIRIS, ALXN1840, CAEL-101, AG10, ALXN2040, ALXN2050, ALXN1720, ALXN1830, ANDEXXA and CERDULATINIB; potential benefits of current products and products under development and in clinical trials; plans for development programs with third parties; and Alexion's future clinical, regulatory, and commercial plans for ULTOMIRIS and other products and product candidates. Non-GAAP income tax expense for the three months ended March 31, 2019 also excludes certain one-time tax benefits of $95.7 million and $30.3 million associated with a tax election made with respect to intellectual property of Wilson and a release of an existing valuation allowance, respectively. Alexion Pharmaceuticals net profit margin as of December 31, 2020 is 9.94% . Alexion’s financial guidance is based on current foreign exchange rates net of hedging activities and does not include the effect of acquisitions, license and other strategic agreements, intangible asset impairments, litigation charges, changes in fair value of contingent consideration, gains or losses related to strategic equity investments or restructuring and related activity outside of the previously announced activities that may occur after the issuance of this press release. Non-GAAP cost of sales was $141.8 million, compared to $95.7 million in the second quarter of 2019. ALXN Inventory-to-Revenue as of today (February 10, 2021) is 0.47. At the heart of everything we do is an intense desire to pursue the toughest challenges and truly change the world for people living with rare and devastating diseases. I am incredibly proud of what we have accomplished so far and am confident that we are well positioned to build on this momentum in the second half of the year.". Do the numbers hold clues to what lies ahead for the stock? Alexion Pharmaceuticals EBITDA for the quarter ending December 31, 2020 was $0.697B , a 10.39% increase year-over-year. A replay of the call will be available for a limited period following the call. Alexion Pharmaceuticals (ALXN) came out with quarterly earnings of $3.11 per share, beating the Zacks Consensus Estimate of $2.55 per share. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for. Alexion Pharmaceuticals ALXN. This position may be located at any Alexion US office, or virtual/remote, with up to 20% travel required. ET. When Alexion released second-quarter earnings on July 30, it forecast 2020 sales of $5.55 billion to $5.6 billion. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. The company is expected to report earnings of $2.59/share on revenue of $1.429 billion. Alexion will host a conference call/audio webcast to discuss the second quarter 2020 results today at 8:00 a.m. Eastern Time. Alexion, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.44 billion for the quarter ended March 2020, surpassing the … Alexion also uses these non-GAAP financial measures to establish budgets, set operational goals and to evaluate the performance of the business. Alexion is increasing total revenues and non-GAAP EPS guidance and decreasing operating margin guidance. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. During the three months ended March 31, 2020, we recorded $21.5 million in litigation charges in connection with ongoing investigations. All rights reserved. Non-GAAP diluted EPS was $3.11, compared to $2.64 in the second quarter of 2019. The audio webcast can be accessed on the Investor page of Alexion’s website at: http://ir.alexion.com. Export Data Save Image Print Image For advanced charting, view our full-featured Fundamental Chart. Non-GAAP income tax expense was $125.5 million, compared to $90.2 million in the second quarter of 2019. The 2020 GAAP and non-GAAP tax rates do not benefit from one-time events that benefited the tax rates in 2019. Media ALEXION PHARMACEUTICALS, INC. - 10-K, Annual Report: 06.02. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Because Alexion will be acquired by AstraZeneca, I am ceasing coverage. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law. This press release and further information about Alexion can be found at: www.alexion.com. The company is expected to report earnings of $2.59/share on revenue of $1.429 billion. Changes in operating assets and liabilities, excluding the effect of acquisitions: Prepaid expenses, right of use operating assets and other assets, Accounts payable, accrued expenses, lease liabilities and other liabilities, Net cash provided by operating activities, Purchases of available-for-sale debt securities, Proceeds from maturity or sale of available-for-sale debt securities, Purchases of mutual funds related to nonqualified deferred compensation plan, Proceeds from sale of mutual funds related to nonqualified deferred compensation plan, Purchases of property, plant and equipment, Payment for acquisition of business, net of cash acquired, Purchases of strategic equity investments and options, Net cash (used in) provided by investing activities, Net proceeds from issuance of common stock under share-based compensation arrangements, Effect of exchange rate changes on cash and cash equivalents and restricted cash, Net change in cash and cash equivalents and restricted cash, Cash and cash equivalents and restricted cash at beginning of period, Cash and cash equivalents and restricted cash at end of period, View source version on businesswire.com: https://www.businesswire.com/news/home/20200506005293/en/, Alexion: Alexion Pharmaceuticals, Inc. ALXN entered into a definitive agreement with U.K.-based pharmaceutical company, ... Last year, it generated $24 billion in global revenues. To participate in the call, dial 866-762-3111 (USA) or 210-874-7712 (International), conference ID 6053185 shortly before 8:00 a.m. Eastern Time. Chris Stevo, 857-338-9309 BOSTON--(BUSINESS WIRE)--May 6, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the third quarter of 2020. GAAP income tax benefit was $284.0 million, compared to income tax expense of $39.7 million in the second quarter of 2019. Alexion Pharmaceuticals earnings and revenue easily beat Q3 views. Alexion plans to re-initiate a Phase II trial in WAIHA during the first quarter of 2020. A replay of the call will be available for a limited period following the call. Acquisition-related costs primarily consist of transaction costs, costs associated with the accelerated vesting of stock options previously granted to Achillion employees and restructuring-related costs. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN) is scheduled to report Q3 earnings results before markets open for trading on October 29, 2020. At Alexion, we are innovators, leaders, and collaborators. Prior to that, the total revenue of 2018 was increasing by 16.33% from US$ 3,551.1 million in 2017. During the three months ended March 31, 2019, we recorded expense of $21.2 million in connection with an upfront payment on a strategic agreement that we entered into with Zealand Pharma A/S. See insights on Alexion Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Changes in fair value of contingent consideration expense for the three months ended March 31, 2019 also include the impact of changes in the expected timing of payments of contingent consideration. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. For the three months ended March 31, 2020, we recorded $38.1 million of acquisition-related costs in connection with the Achillion acquisition. The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Chris Stevo, 857-338-9309 The biotech giant also raised full-year guidance, after saying it would. Megan Goulart, 857-338-8634 Alexion (ALXN) delivered earnings and revenue surprises of 25.10% and 11.55%, respectively, for the quarter ended September 2020. This press release and further information about Alexion can be found at: www.alexion.com. Adjustments to reconcile net income to net cash flows from operating activities: Unrealized (gain) loss on forward contracts, Unrealized loss (gain) on strategic equity investments. Alexion Pharmaceuticals (NASDAQ:ALXN) Q3 2020 Earnings Call Oct 29, 2020, 8:00 a.m. Alexion (ALXN) delivered earnings and revenue surprises of 18.40% and 5.70%, respectively, for the quarter ended December 2020. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization. Background . The non-GAAP results, determined in accordance with our internal policies, exclude the impact of the following GAAP items (see reconciliation tables below for additional information): share-based compensation expense, fair value adjustment of inventory acquired, amortization of purchased intangible assets, changes in fair value of contingent consideration, restructuring and related expenses, upfront payments related to licenses and other strategic agreements, acquired in-process research and development, impairment of purchased intangible assets, gains and losses related to strategic equity investments, litigation charges, gain or loss on sale of a business or asset, gain or loss related to purchase options, contingent milestone payments associated with acquisitions of legal entities accounted for as asset acquisitions, acquisition-related costs and certain adjustments to income tax expense. http://www.businesswire.com/news/home/20200730005199/en, © 1985 - 2021 BioSpace.com. Number 7 – Alexion Alexion Pharmaceuticals new headquarters in Boston’s Seaport District Photo: Google Maps. "Our teams have demonstrated remarkable resilience and agility in their successful navigation of the uncertain COVID-19 pandemic environment. Alexion (ALXN) delivered earnings and revenue surprises of 18.40% and 5.70%, respectively, for the quarter ended December 2020. Total revenues in the second quarter were $1,444.6 million, a 20 percent increase compared to the same period in 2019. ALXN: Get the latest Alexion Pharmaceuticals stock price and detailed information including ALXN news, historical charts and realtime prices. On a GAAP basis, diluted EPS in the quarter was $2.50, a 4 percent decrease versus the prior year. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines. GAAP diluted EPS was $(4.84), inclusive of impairment charges of $2,053.3 million primarily relating to the KANUMA intangible asset, compared to $2.04 in the second quarter of 2019. Looking back at the last five years, Alexion Pharmaceuticals's revenue peaked in March 2020 at $5.295 billion. Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN) is scheduled to report Q3 earnings results before markets open for trading on October 29, 2020. Find the latest Revenue & EPS data for Alexion Pharmaceuticals, Inc. Common Stock (ALXN) at Nasdaq.com. BY Fraser Tennant In one of the year’s largest drug mergers, multinational pharmaceutical and biopharmaceutical company AstraZeneca is to acquire US biopharmaceutical company Alexion Pharmaceuticals, Inc. in a transaction valued at $39bn. As of 30 September 2020, Alexion had gross assets of $17.5bn. This … Under the terms of the definitive agreement, Alexion … Media Start your Free Trial. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for, or superior to, the financial measures prepared and presented in accordance with GAAP, and should be reviewed in conjunction with the relevant GAAP financial measures. Overview: Continued strong revenue growth. Despite these challenges, we have delivered another strong quarter and continue to advance our LEAD-EXPAND-DIVERSIFY strategy for long-term value creation," said Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion. Please refer to the attached Reconciliations of GAAP to non-GAAP Financial Results and GAAP to non-GAAP 2020 Financial Guidance for explanations of the amounts adjusted to arrive at non-GAAP net income and non-GAAP earnings per share amounts for the three month periods ended March 31, 2020 and 2019 and projected twelve months ending December 31, 2020. Total revenues in the third quarter were $1,588.7 million , a 26 percent increase compared to the same period in 2019. The negative impact of foreign currency on total revenues year-over-year was 1 percent, or $15.7 million, inclusive of hedging activities. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. In rare diseases, you don’t transform into billions of revenues overnight It’s been a long day already, but, with a quick sip of a soft drink, Julie O’Neill gets stuck in. To participate in the call, dial 866-762-3111 (USA) or 210-874-7712 (International), conference ID 1645087 shortly before 8:00 a.m. Eastern Time. 50 80 110 140 170 200 Updated 2020 financial guidance assumes a GAAP effective tax rate of 15.0 to 16.0 percent and a non-GAAP effective tax rate of 15.5 to 16.5 percent. Browse... View Full Chart Revenue (TTM) Chart . Historical Revenue (TTM) Data. Fueled by chronic undervaluation despite the solid financials and a rich pipeline, Alexion Pharmaceuticals, Inc. has frequently been the subject of acquisition rumors as investors demand a sale of the company.Management has revised up the 2020 revenue guidance twice over the past three months, but the shares have underperformed the broader market in the year so far. Alexion Pharmaceuticals's revenue hit its five-year low in December 2015 of $2.604 billion. Number of employees: 2,525 2019 revenue: $4.991 billion Headquarters: Boston, Mass., U.S. KANUMA net product sales were $33.6 million, compared to $26.2 million in the second quarter of 2019, representing a 28 percent increase.
Instant Cold Compress, Fisher-price Spacesaver Jumperoo, Manuel Mairhofer Instagram, Carina Walz Geboren, Beauty Baby Spieluhr Elefant, Rhodeländer Hühner Kaufen österreich, Hallenhockey Bundesliga Damen,